Dr Reddys Labs Standalone September 2022 Net Sales at Rs 4,880.30 crore, up 27.64% Y-o-Y
NULL28-10-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Letter of Confirmation in lieu of share certificate(s) reported lost/misplaced28-10-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter And Half-Year Ended September 30, 2022
Outcome of Board Meeting - Unaudited Financial Results for the quarter and half-year ended September 30, 202228-10-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Disclosure under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 201528-10-2022
Dr Reddy's Q2 preview: Pharma major likely to report sharp drop net profit on weak US biz
Dr Reddy's North American operations will set the tone for the September quarter performance, as likely price erosion will trigger a decline in sales on a year-on-year basis27-10-2022
Dr Reddy's, Cipla, and Aurobindo units recall products in US market
Leading drug firms Dr Reddy's Laboratories, Cipla and Aurobindo Pharma are recalling different products in the US market for various issues, according to the US Food and Drug Administration. As per the enforcement report by the US Food and Drug Administration (USFDA), the US-based unit of Dr Reddy's Laboratories is recalling 2,838 ampules of vitamin K deficiency treatment drug Phytonadione Injectable Emulsion. According to the USFDA, Dr Reddy's Laboratories is recalling the affected lot due to "failed stability specifications". "Out of specification results reported at 12-month stability testing for aluminum content," it stated. Dr Reddy's initiated the Class III voluntary recall on September 14 this year. As per USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences". USFDA further said the US-based arm of domestic drug major Cipla is recalling 9,041 cartons of Arformoterol ..23-10-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Outcome Of Postal Ballot
Results of voting through Postal Ballot pursuant to Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for appointment of Mr. Arun Madhavan Kumar (DIN: 09665138), as an Independent Director in terms of Section 149 of the Companies Act, 201321-10-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Earnings Call Notification: Q2 FY23
Earnings Call Notification: Q2 FY2313-10-2022
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication- Loss of Share Certificates13-10-2022
WEF recognises Dr. Reddy's Hyderabad unit as part of GLN
GLN is a WEF initiative in collaboration with McKinsey & Company. Factories and value chains that join GLN are designated by an independent panel of experts.11-10-2022